Analysts say the adoption of GLP-1 drugs, the expansion of AI and the growth of multi-billion-dollar M&A deals chart an unpredictable path for the industry this year.

The findings are a result of an in-depth qualitative study based on interviews with more than 50 marketing and capability leaders around the world ...

We recently compiled a list of the Jim Cramer Shed Light on These 9 Stocks. In this article, we are going to take a look at ...